- Home
- BEEP vs BDTX Comparison
BEEP vs BDTX Comparison
Compare BEEP & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BEEP | BDTX |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.1M | 104.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BEEP | BDTX |
|---|---|---|
| Price | $2.48 | $1.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $5.83 | ★ $10.00 |
| AVG Volume (30 Days) | 19.6K | ★ 871.5K |
| Earning Date | 11-10-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,075,000.00 | N/A |
| Revenue This Year | $1.47 | N/A |
| Revenue Next Year | $11.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.29 | $1.60 |
| 52 Week High | $3.53 | $4.94 |
Technical Indicators
Market Signals| Indicator | BEEP | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.87 | 48.68 |
| Support Level | $2.26 | $1.65 |
| Resistance Level | $2.44 | $1.93 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 34.68 | 37.21 |
Price Performance
Historical ComparisonAbout BEEP Mobile Infrastructure Corporation
Mobile Infrastructure Corp focus on acquiring, owning and optimizing parking facilities and related infrastructure, including parking lots, parking garages, and other parking structures throughout the United States. It operates in a single reportable segment: parking. The parking segment derives revenue from managed property revenue and rental income at parking facilities. The company provides access to property and space for the parker's vehicle and charges fees that vary based on the level of usage. The company derives all of its revenue domestically.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.